Lipofibromatous hamartoma: review of early diagnosis and treatment

Anoush Razzaghi, MD; Dimitri J. Anastakis, MD, MEd

**Background:** Lipofibromatous hamartoma (LFH) is a rare tumour that requires early diagnosis and treatment. To alert physicians to the possibility of this tumour, we review the epidemiologic and pathological characteristics, the presentation, diagnosis and treatment of LFH in the upper extremity.

**Methods:** We obtained data from a MEDLINE search of the English literature from 1966 to June 2003, using the search terms “lipofibromatous,” “hamartomas of the nerve,” “macrodactyly” and “intraneurial lipoma.” **Study selection:** Articles that demonstrated institutional experience (epidemiologic, diagnostic and therapeutic, and complications) and those that provided general reviews were selected for inclusion. Of 501 identified articles, 42 fulfilled the review criteria. **Data extraction:** Relevant clinical, diagnostic and therapeutic evaluations were extracted from the literature and synthesized. **Data synthesis:** LFH is distinguished pathologically from other intraneural tumours by fibrofatty infiltration around the nerve fascicles. Typically, patients present either early with macrodactyly or later with a forearm mass lesion or symptoms consistent with a compressive neuropathy of the affected nerve. Although MRI is an important tool in the diagnosis of LFH, the diagnosis should be supported with a tissue biopsy. Treatment for patients with no neurologic deficit involves prophylactic decompression of affected nerves at all points of possible compression. Patients with macrodactyly may benefit from debulking, joint reconstruction or amputation. **Conclusions:** LFH differs from other benign nerve tumours with respect to clinical presentation, pathological characteristics, MRI features and management. Because LFH is extensive and inseparable from the nerve fascicles, excision is not recommended.

**Contexte :** L’hamartome lipofibromateux (HLF) est une tumeur rare qu’il faut diagnostiquer et traiter rapidement. Afin de prévenir les médecins de la présence possible de cette tumeur, nous passons en revue les caractéristiques épidémiologiques et pathologiques, la présentation, le diagnostic et le traitement de l’HLF du membre supérieur. **Méthodes :** Nous avons extrait des données par recherche MEDLINE dans des publications en anglais de 1966 à juin 2003 en utilisant les termes «lipofibromatous», «hamartomas of the nerve», «macrodactyly» et «intraneurial lipoma». ** Sélection des études :** On a choisi d’inclure les articles qui démontraient l’expérience de l’établissement (épidémiologie, diagnostic, traitement et complications) et ceux qui présentaient des analyses générales. Sur 501 articles repérés, 42 satisfaisaient aux critères d’examen. **Extraction des données :** On a extrait et résumé, à partir des publications, des évaluations cliniques, diagnostiques et thérapeutiques pertinentes. **Synthèse des données :** On a établi une distinction, sur le plan pathologique, entre l’HLF et d’autres tumeurs nerveuses par son infiltration de tissus fibrograisseux autour des faisceaux nerveux. Habituellement, les patients se présentent soit au début avec une macrodactylye, soit plus tard avec une masse à l’avant-bras ou des symptômes correspondant à une neuropathie compressive du nerf touché. Même si l’IRM constitue un outil important dans le diagnostic de l’HLF, il faut appuyer le diagnostic par une biopsie tissulaire. Dans le cas des patients qui n’ont pas de déficit neurologique, le traitement comporte une décompression prophylactique des nerfs atteints à tous les points de compression possibles. La chirurgie de réduction tumorale, la reconstruction de l’articulation ou l’amputation peuvent être bénéfiques pour les patients atteints de macrodactylye. **Conclusions :** L’HLF diffère d’autres tumeurs nerveuses bénignes sur le plan de la présentation clinique, des caractéristiques pathologiques, des résultats de l’IRM et de la prise en charge. Comme l’HLF est étendu et inséparable des faisceaux nerveux, l’excision n’est pas recommandée.

From the Toronto Western Hospital, University Health Network, Toronto, Ont.


Accepted for publication July 7, 2004.

**Correspondence to:** Dr. Dimitri J. Anastakis, Divisions of Plastic and Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto Western Hospital, University Health Network, 2 East Wing, 399 Bathurst St., Toronto ON M5T 2S8; fax 416 603-6189; dimitri.anastakis@uhn.on.ca
Lipofibromatous hamartoma (LFH) is a benign, extremely rare intraneural tumour, which needs to be differentiated from other more common peripheral nerve tumours such as intraneural lipomas. It affects the peripheral nerves, most commonly in the upper extremity. Unlike other nerve tumours, LFH cannot be excised but requires early prophylactic decompression at points of potential compression in order to avoid permanent nerve damage. LFH was first reported by Mason in 1953 and then by several others. Synonyms for the condition include: fatty infiltration, intraneural lipofibroma, fibrofatty proliferation, lipofibroma, and hamartoma, but LFH is currently the most accepted name. LFH is associated with macrodactyly in more than one-third of cases. Patients present early in childhood with macrodactyly or later in adolescence with a volar forearm mass. Symptoms consistent with compressive neuropathy of affected peripheral nerves can also occur later in life. Traditionally, management has included decompression of symptomatic nerves at points of compression and debulking of soft tissues or, in patients with severe macrodactyly, amputation. Radical excision of the affected nerve is not recommended. In this review, we will alert physicians to this rare form of nerve tumour that requires early diagnosis and treatment.

Methods

For this review we selected articles from a MEDLINE search of the English language literature from 1966 to June 2003. Further references from the bibliographies of these articles were identified and reviewed. The search terms used were “lipofibromatous,” “hamartomas of the nerve,” “macrodactyly” and “intraneural lipoma.”

Study selection

We identified 501 articles; of these, 42 articles and selected reviews demonstrated institutional experience (epidemiology, diagnosis, treatment, complications) or were general reviews.

Data extraction

From these 42 articles and reviews, we extracted all relevant etiologic, epidemiologic, pathological, diagnostic and therapeutic information and synthesized the data.

Data synthesis

Etiology and epidemiology

The etiology of LFH is unclear, although several potential etiologic factors have been described, including abnormal development of flexor retinaculum in children, antecedent trauma and chronic nerve irritation. Many authors believe that LFH is a congenital condition. It most commonly manifests well before the third decade, although several reports have described patients who first presented past the fifth decade. The condition is most common among white people. It occurs sporadically across populations and has no association with neurofibromatosis. LFH commonly results in digital enlargement due to an increase in perineural soft tissue and skin. When accompanied by true macrodactyly, the tumour is referred to as macrodystrophy lipomatosa. More than one-third of LFHs are associated with macrodactyly. Females are more commonly affected when macrodactyly is present; when LFH is not associated with macrodactyly, both males and females are equally affected.

The distal peripheral nerves are most often affected in LFH; cranial nerve involvement is rare. LFH involves the upper extremities 3 times more frequently than the lower extremities, and specifically the median nerve. Cases of LFH affecting the entire brachial plexus, proximal ulnar nerve, distal ulnar nerve, superficial branch of the radial nerve, superficial peroneal nerve and the medial plantar nerve of the foot have also been reported.

Pathological findings

Gross findings

On gross pathological examination, LFH consists of lobulated, soft, grey-yellow, sausage-shaped masses within the epineural sheath (Fig. 1). Nerves may be markedly increased in length and diameter in the involved area (Fig. 2); indeed, cases of fusiform median nerve enlargement of up to 17 cm in length and 30 mm in diameter have been reported. LFH can be extensive and follow nerves even up the brachial plexus. Along their course, the affected peripheral nerves do not adhere to surrounding tissue. In some instances, hypertrophy of surrounding skin and soft tissue is associated with the enlargement of the bone (macrodystrophy lipomatosa).

Microscopic findings

In LFH, the diffuse involvement of the nerve showing relatively bland histologic changes is consistent with a hamartomatic rather than a neoplastic tumour. The lesion is described as a hamartoma because of the overgrowth of the normal connective tissue constituents: fat and fibrous tissue (Fig. 3, left). Histopathological examination shows infiltration of the epineurium by fibrofatty tissue, which separates and compresses the nerve fascicles. This infiltration causes atrophy of the neural elements, often accompanied by extensive perineural fibrosis. Axonal loss and collagen deposition add further chronic changes. In one case reported by Louis and Dick, a biopsy specimen of the median nerve showed the presence of fat and heterotopic bone, an occurrence that is very uncommon. The affected nerve may display other...
features in addition to adipose tissue, such as perineural seption of nerve fascicles and microfascicle formation. Pseudo-onion bulb-like hypertrophic change is an effect of the increase in perineural cells. Although this condition resembles intraneural perineuroma, it should not be misdiagnosed as such (Fig. 3, right).

**Histologic differential diagnosis**

Other benign soft-tissue tumours in the upper extremity need to be distinguished from LFH; these include neurilemmomas, neurofibromas and intraneural lipomas. LFH differs from other intraneural tumours by its characteristic fibrofatty infiltration around the nerve fascicles. Neurilemmomas and neurofibromas arise from Schwann cells. Neurilemmomas are encapsulated tumours, extrinsic to the nerve fibres and easily separated from the nerve fascicles. Neurofibromas are not encapsulated and show intermingling with the nerve fascicles. Intraneural lipomas arise from normally occurring adipose cells within the nerve; like neurilemmomas, they are encapsulated and easily detached from the nerve fascicles. Finally, intraneural ganglia have been described in the histologic differential diagnosis. Unlike LFH, neurilemmomas, intraneural lipomas and intraneural ganglia do not intermingle with nerve fascicles.

**Clinical presentation**

The most frequent presentation of LFH is a swelling or mass on the volar aspect of the wrist or distal forearm. The mass usually appears...
several years before the onset of neurologic symptoms. Neurologic deterioration ensues after some years. Associated clinical symptoms include pain and numbness, along with motor and sensory deficits in the median nerve distribution. Since most of these tumors involve the median nerve, the symptoms are caused by the compression of this nerve in the carpal tunnel.

The macrodactyly with which LFH is commonly associated can be present at birth or can be diagnosed during early childhood. When present, macrodactyly can be symmetric — involving equally the radial or ulnar sides of the same digit — or asymmetric. Although the phalanges are usually affected, the metacarpals are involved inconsistently. According to Dell, the involvement of metacarpals often occurs in older patients and is a manifestation of the severity of the disorder. Macroductyly is unilateral 90% of the time. The majority of patients with macroductyly present in their first to third decades because of aesthetic concerns (Fig. 4).17

Diagnosis

A carefully taken history and physical examination are the cornerstones of the correct diagnosis of LFH. Plain radiographs are valuable for assessing changes in the underlying skeleton when macroductyly is present (Fig. 5). In some cases, a biopsy of the palmar cutaneous branch or the dorsal ulnar portion of the median nerve has been obtained to confirm the diagnosis. When this is done, the biopsy should be studied by an experienced neuropathologist so that malignant lesions such as neurofibrosarcomas can be ruled out. MRI plays a major role in confirming the diagnosis of LFH. It is now being recommended for all patients suspected of having the condition. Cases are being identified more frequently as the use of MRI increases. MRI not only confirms the diagnosis, it also provides a detailed assessment of nerve involvement preoperatively. A characteristic feature on MRI is the appearance of serpentine nerve fascicles surrounded by fibrofatty tissue within the expanded nerve sheath. Distribution of fat between fascicles is asymmetric. On coronal images, the nerve has a spaghetti-like appearance that is pathognomonic for LFH. Although MRI is an important tool in the diagnosis of LFH, the diagnosis should be supported with a tissue biopsy, particularly in cases presenting as an asymptomatic mass lesion or in centres without a large clinical experience in dealing with rare peripheral nerve tumours.

Electromyography and nerve conduction studies (EMG-NC) can also provide valuable information needed to confirm a diagnosis of LFH. EMG-NC can show prolonged distal latency of sensory or motor innervation and fibrillations in distal muscles to confirm a compressive neuropathy.11,26,29

Treatment

Surgical excision of LFH is not recommended for several reasons. First,
the effects of excision are devastating in terms of motor and sensory function. Second, patients may suffer neurogenic pain after resection. Third, LFH can involve the entire nerve all the way up to the plexus, making the resection margins difficult if not impossible to identify.

In cases of LFH without macrodactyly, most authors agree with a conservative approach that includes decompression of all compromised peripheral nerves to help alleviate pain and paresthesia to reduce the likelihood of permanent motor and sensory sequelae. If the dislikelihood of permanent motor and pain and paresthesia to reduce the decompression of all compromised conservative approach that includes dactyly, most authors agree with a cult if not impossible to identify. making the resection margins difficult may benefit from debulking, joint reconstruction or amputation. Patients who present late with advanced disease may benefit from reconstructive procedures aimed at improving hand function. Radical excision of these tumours is not recommended.

Conclusions

Our understanding of this rare benign tumour of the peripheral nerves remains limited. LFH differs from other intraneural tumours owing to its characteristic fibrofatty infiltration around the nerve fascicles, which, unlike other nerve tumours, rules out excision. LFH requires early prophylactic decompression at points of potential compression in order to avoid permanent nerve damage. Patients with significant macrodactyly may benefit from debulking, joint reconstruction or amputation. Patients who present late with advanced disease may benefit from reconstructive procedures aimed at improving hand function. Radical excision of these tumours is not recommended.

Competing interests: None declared.

References


How you can get involved in the CMA!

The CMA is committed to providing leadership for physicians and promoting the highest standard of health and health care for Canadians. To strengthen the Association and be truly representative of all Canadian physicians, the CMA needs to hear from members interested in serving in elected positions and on appointed committees and advisory groups.

The CMA structure comprises both governing bodies and advisory bodies either elected by General Council or appointed by the CMA Board of Directors. The Board of Directors — elected by General Council — has divisional, affiliate, resident and student representation, is responsible for the overall operation of the CMA and reports to General Council on issues of governance. CMA councils and committees advise the Board of Directors and make recommendations on specific issues of concern to physicians and the public. Four core councils and committees consist of either divisional or regional representation, while other statutory and special committees, and expert working and project advisory groups comprise individuals with interest and expertise in subject-specific fields. Positions on one or more of these committees may become available in the coming year.

For further information on how you can get involved, please contact:

Paula Wilson
Strategic & Corporate Affairs
Canadian Medical Association
1867 Alta Vista Drive
Ottawa ON K1G 3Y6
Fax 613 526-7570
Tel 800 663-7336 x2047
involved@cma.ca

By getting involved, you will have an opportunity to make a difference.

We hope to hear from you!